PTC Therapeutics (PTCT) got here out with a quarterly lack of $0.89 per share versus the Zacks Cons
PTC Therapeutics (PTCT) got here out with a quarterly lack of $0.89 per share versus the Zacks Consensus Estimate of a lack of $0.91. This compares to lack of $0.94 per share a yr in the past. These figures are adjusted for non-recurring objects.
This quarterly report represents an earnings shock of two.20%. 1 / 4 in the past, it was anticipated that this biopharmaceutical firm would submit a lack of $0.46 per share when it truly produced a lack of $0.66, delivering a shock of -43.48%.
Over the past 4 quarters, the corporate has surpassed consensus EPS estimates simply as soon as.
PTC Therapeutics, which belongs to the Zacks Medical – Medicine business, posted revenues of $71.42 million for the quarter ended September 2019, surpassing the Zacks Consensus Estimate by 5.78%. This compares to year-ago revenues of $53.59 million. The corporate has topped consensus income estimates thrice during the last 4 quarters.
The sustainability of the inventory’s rapid worth motion based mostly on the…